Skip to main content
. 2020 Oct 20;41(7):1634–1646. doi: 10.1177/0271678X20965500

Figure 4.

Figure 4.

Caspase-3 activation in hESC-derived cerebral organoids. Organoids were incubated for 24 h with medium with 0.1% DMSO (DMSO control), erlotinib hydrochloride (10 µg/mL, erlotinib), tariquidar dimesylate (5 µg/mL, tariquidar) and a combination of erlotinib hydrochloride (10 µg/mL) and tariquidar dimesylate (5 µg/mL) (erlotinib/tariquidar) (n = 1 cerebral organoid per treatment with eight slices analyzed per cerebral organoid). Results are expressed as percent of DMSO control. ***p < 0.001, one-way ANOVA with Dunnett’s multiple comparisons test.